Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.92 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | LPAR5 | Q9H1C0 | 4/20 | 0.60 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.54 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.44 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.44 |
| ▸ | LPAR2 | Q9HBW0 | 4/20 | 0.44 |
| ▸ | LPAR6 | P43657 | 3/20 | 0.44 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13299402 | 1.00 | USP2 (0.92) | USP2HTTLPAR5SPHK1PLA2G2C | |
| SCHEMBL14894108 | 1.00 | USP2 (0.92) | USP2HTTLPAR5SPHK1PLA2G2C | |
| SCHEMBL9813396 | 1.00 | USP2 (0.92) | USP2HTTLPAR5SPHK1PLA2G2C | |
| SCHEMBL14894009 | 1.00 | USP2 (0.92) | USP2HTTLPAR5SPHK1PLA2G2C | |
| SCHEMBL14893765 | 1.00 | USP2 (0.92) | USP2HTTLPAR5SPHK1PLA2G2C | |
| SCHEMBL9813384 | 1.00 | USP2 (0.92) | USP2HTTLPAR5SPHK1PLA2G2C | |
| SCHEMBL15435146 | 1.00 | USP2 (0.92) | USP2HTTLPAR5SPHK1PLA2G2C | |
| SCHEMBL14894192 | 1.00 | USP2 (0.92) | USP2HTTLPAR5SPHK1PLA2G2C | |
| SCHEMBL9813400 | 1.00 | USP2 (0.92) | USP2HTTLPAR5SPHK1PLA2G2C | |
| SCHEMBL9813406 | 1.00 | USP2 (0.92) | USP2HTTLPAR5SPHK1PLA2G2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| US-20120064147-A1 | AGENT FOR IMPROVING TISSUE PENETRATION | GENZYME CORPORATION (US) | 2012-03-15 | — | — | US | claimed |
| US-20090312440-A1 | AGENT FOR IMPROVING TISSUE PENETRATION | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSHAFTEN E.V. (DE) | 2009-12-17 | — | — | US | claimed |
| US-20080003277-A1 | Agent for improving tissue penetration | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSHAFTEN E.V. (DE) | 2008-01-03 | — | — | US | claimed |
| EP-1387699-B1 | AGENT FOR IMPROVING TISSUE PENETRATION | MAX PLANCK GESELLSCHAFT (DE) | 2006-11-29 | — | — | EP | claimed |
| US-20040146535-A1 | Agent for improving tissue penetration | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSHAFTEN E.V. (DE) | 2004-07-29 | — | — | US | claimed |
| EP-1387699-A1 | AGENT FOR IMPROVING TISSUE PENETRATION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2004-02-11 | — | — | EP | claimed |
| WO-2002092130-A1 | AGENT FOR IMPROVING TISSUE PENETRATION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2002-11-21 | — | — | WO | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | disclosed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | disclosed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | disclosed |
| US-20160031781-A1 | AGENT FOR IMPROVING TISSUE PENETRATION | GENZYME CORPORATION (US) | 2016-02-04 | — | — | US | disclosed |
| US-20080003277-A1 | Agent for improving tissue penetration | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSHAFTEN E.V. (DE) | 2008-01-03 | — | — | US | disclosed |
| EP-1387699-B1 | AGENT FOR IMPROVING TISSUE PENETRATION | MAX PLANCK GESELLSCHAFT (DE) | 2006-11-29 | — | — | EP | disclosed |
| US-20040146535-A1 | Agent for improving tissue penetration | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSHAFTEN E.V. (DE) | 2004-07-29 | — | — | US | disclosed |
| EP-1387699-A1 | AGENT FOR IMPROVING TISSUE PENETRATION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2004-02-11 | — | — | EP | disclosed |
| WO-2002092130-A1 | AGENT FOR IMPROVING TISSUE PENETRATION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080003277-A1 | Agent for improving tissue penetration | PGF, MMP8, MMP1 | USP2 3018/4885HTT 3525/4885LPAR5 176/4885 |
| US-20040146535-A1 | Agent for improving tissue penetration | PGF, MMP8, MMP1 | USP2 3018/4885HTT 3525/4885LPAR5 176/4885 |
| US-20090312440-A1 | AGENT FOR IMPROVING TISSUE PENETRATION | PGF, MMP8, MMP1 | USP2 3018/4885HTT 3525/4885LPAR5 176/4885 |
| US-20160031781-A1 | AGENT FOR IMPROVING TISSUE PENETRATION | PGF, MMP8, MMP1 | USP2 3018/4885HTT 3525/4885LPAR5 176/4885 |
| US-20120064147-A1 | AGENT FOR IMPROVING TISSUE PENETRATION | PGF, MMP8, MMP1 | USP2 3018/4885HTT 3525/4885LPAR5 176/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | USP2 2044/4885HTT 345/4885LPAR5 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.